The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 13, 2023

Filed:

Oct. 08, 2020
Applicant:

Hoffmann-la Roche Inc., Little Falls, NJ (US);

Inventors:

Michael Huelsmann, Habach, DE;

Erhard Kopetzki, Penzberg, DE;

Assignee:

Hoffmann-La Roche Inc., Little Falls, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61P 27/02 (2006.01); C07K 16/46 (2006.01); C07K 14/78 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 47/65 (2017.08); A61K 47/6879 (2017.08); A61P 27/02 (2018.01); C07K 16/46 (2013.01); A61K 2039/505 (2013.01); C07K 14/78 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01);
Abstract

The combination of a first binding site specifically binding to a target associated with an eye disease and a second binding site specifically binding to a target influencing the retention in the eye a multispecific binder provides for improved intravitreal retention compared to a monospecific binder. The second binding site specifically binds to a compound/molecules found in the extracellular matrix (ECM) in vitreous humor/retina. This compound of the extracellular matrix has to be present in amounts allowing a sufficient loading/dose of the drug to be bound. It has been found that collagen, especially collagen II, is a suitable compound in the ECM in the vitreous humor for this purpose. Thus, herein is reported a multispecific binder comprising a first binding site specifically binding to a therapeutic ocular target, and a second binding site specifically binding to collagen II.


Find Patent Forward Citations

Loading…